Status:
RECRUITING
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
Lead Sponsor:
Qualigen Theraputics, Inc.
Collaborating Sponsors:
Translational Drug Development
Conditions:
Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body...
Eligibility Criteria
Inclusion
- Patients with histologically confirmed locally advanced or metastatic solid carcinomas, who have had tumor progression after receiving all standard of care therapies or for which there is no approved therapy 2. Evaluable or measurable disease by RECIST 1.1
Exclusion
- \-
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT06086522
Start Date
November 1 2023
End Date
December 1 2026
Last Update
May 1 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
HonorHealth
Scottsdale, Arizona, United States, 85251
2
Yale
New Haven, Connecticut, United States, 06520
3
START Midwest
Grand Rapids, Michigan, United States, 49546
4
MD Anderson Cancer Center
Houston, Texas, United States, 77002